NATCO Pharma Limited (BOM:524816)
817.00
-4.50 (-0.55%)
At close: Nov 20, 2026
NATCO Pharma Revenue
NATCO Pharma had revenue of 9.67B INR in the quarter ending September 30, 2026, a decrease of -29.03%. This brings the company's total for the last twelve months to 30.92B, down -29.56% year-over-year. In the fiscal year ending March 31, 2026, NATCO Pharma had annual revenue of 40.82B, down -7.90%.
Revenue (ttm)
30.92B
Revenue Growth
-29.56%
P/S Ratio
5.17
Revenue / Employee
6.98M
Employees
4,433
Market Cap
159.74B
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full NATCO Pharma breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 40.82B | -3.50B | -7.90% |
| Mar 31, 2025 | 44.32B | 4.30B | 10.74% |
| Mar 31, 2024 | 40.02B | 12.94B | 47.76% |
| Mar 31, 2023 | 27.09B | 7.62B | 39.17% |
| Mar 31, 2022 | 19.46B | -1.10B | -5.35% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Piramal Pharma | 97.79B |
| Alembic Pharmaceuticals | 84.77B |
| Strides Pharma Science | 52.13B |
| Akums Drugs and Pharmaceuticals | 48.29B |
| Wockhardt | 38.40B |
| Eris Lifesciences | 33.12B |
| NATCO Pharma | 30.92B |
| Alivus Life Sciences | 26.84B |
NATCO Pharma News
- 9 days ago - NATCO Pharma Transcript: Q2 26/27 - Transcripts
- 9 days ago - NATCO Pharma Quarterly report: Q2 2027 - Filings
- 9 days ago - NATCO Pharma Slides: Q2 2027 - Filings
- 1 month ago - Natco Pharma to raise ₹1,279 crore via rights issue - The Times of India
- 3 months ago - Natco’s AP formulations unit gets USFDA Form 483 with 4 observations - The Times of India
- 3 months ago - NATCO Pharma Transcript: Q1 26/27 - Transcripts
- 3 months ago - NATCO Pharma Quarterly report: Q1 2027 - Filings
- 3 months ago - NATCO Pharma Slides: Q1 2027 - Filings